Topic
Biotech
245 published works
RF EMerge
Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies
Capsida Biotherapeutics Inc.—a Thousand Oaks, CA-based emerging biotechnology company—recently emerged from stealth mode with $ 140 million in start-up capital. Capsida secured a $50 million Series A commitment from Versant…
The Daily Intake
EU Considers Benefits of New Genomic Techniques
On April 29, 2021, the European Commission published a study considering the status of “new genomic techniques” (NGTs) under EU law. The study defined NGTs as techniques for altering genetic…
Big Molecule Watch
CytoImmune Therapeutics and Biosimilar Sciences US to Move Biotechnology Operations to Puerto Rico
By Audie Soucy
With the support of the economic development organization Invest Puerto Rico, Biosimilar Solutions LLC announced that both it and CytoImmune Therapeutics will be establishing operations on the island to conduct…
Israel Global Gateway
Guest blog: China signs off on first PRC Biosecurity Law: What this means for Israeli companies in China?
By Israel Group
By Ting Xiao, Horace Lam and William Fisher On 17 October 2020, the Standing Committee of the PRC National People’s Congress (“NPC”) passed the first PRC Biosecurity Law, which will…
Biosimilars Law Bulletin
Does the Term “Human Antibody” Include Humanized Antibodies?
By Alvin Lee
In the context of Immunex’s patent on IL-4 antibodies, the Federal Circuit says yes. On October 13, 2020, the Federal Circuit affirmed the Patent Trial and Appeal Board’s (the “Board”)…
GT Israel Law Blog
Bob Grossman to Moderate JNF’s Virtual Event on US-Israeli Innovations in the Life Sciences
As part of their free Lunch & Learn speaker series, Jewish National Fund-USA (JNF-USA) will be hosting a discussion about innovation in the realms of biotechnology, pharmaceuticals, and agricultural technology…
RF EMerge
Cambridge Startup Walden Biosciences Launches With $50M Raise
By Dan Shores
Cambridge startup biotechnology company Walden Biosciences announced its launch today with a $51 million Series A financing led by UCB Ventures and ARCH Venture Partners. Walden is seeking to develop…
Big Molecule Watch
Low-Cost Syringe Technology May Enable Subcutaneous Injection of Viscous Formulations
In late August, MIT announced that a group of MIT researchers led by Kripa Varanasi published a paper describing a low-cost technology for administering biological drug formulations otherwise too viscous to be injected using…
The CLS Blue Sky Blog
Deregulating Innovation Capital: The Effects of the JOBS Act on Biotech Startups
By Craig M. Lewis, Joshua T. White
Since the start of the COVID-19 pandemic, everyone from politicians to reporters to ordinary Americans have been talking about drug treatments, vaccines, and the Federal Drug Administration (FDA) approval process.…
China Law Insight
注目のバイオテクノロジー分野特許出願の戦略と提案
By King & Wood
試験的学科であるため、バイオテクノロジー分野の予測可能性は低く、特許審査では技術的効果の予期可能の程度について、常に論争が生じている。例えば、審査官は、発明の技術的効果が予期できないため請求項が明細書にサポートされていないと主張する可能性がある。また、その逆、本分野において原理的な指導や、具体的な方向性のない普遍的な技術的要求のみが存在する場合に、従来技術が改良の動機を与えており、技術的効果が合理的に予期できると主張する可能性もある。このような審査意見は、確実な証拠がない場合には反論することが非常に難しい。以下、具体例をいくつか挙げて、上述の状況を説明する。